Skip to content

Interest of Intravaginal Electro-stimulation at Home by GYNEFFIK® Compared to Usual Care in Incontinent Patients With Prior Perineal Reeducation

Evaluation de l'intérêt de l'électrostimulation Intra-vaginale à Domicile Par Rapport à Une Prise en Charge Habituelle Dans la Prise en Charge de Patientes Incontinentes Ayant bénéficié d'Une rééducation périnéale

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02029027
Enrollment
163
Registered
2014-01-07
Start date
2012-08-31
Completion date
2014-02-28
Last updated
2014-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Mixed Incontinence, Urinary Stress Incontinence

Keywords

Urinary Stress Incontinence, Urinary Mixed Incontinence

Brief summary

The aim of this study is to assess the benefit of GYNEFFIK®, a perineal electro-stimulator, during this home-care phase. Women with stress urinary incontinence (UI) or with mixed UI (composed predominantly of stress UI), that responded to physiotherapy were included in this study in two parallel groups. The groups followed a self-reeducation program, with or without GYNEFFIK® electro-stimulation sessions. The comparison of the two groups was based on the rate of women for whom the benefit of the initial perineal reeducation was maintained.

Interventions

DEVICEGYNEFFIK(R)

Vaginal electro-stimulation medical device

OTHERUsual Care

Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation

Sponsors

Effik
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* out-patient over 18 years old, having understood and signed the Informed Consent Form * seen for urinary stress incontinence or urinary mixed incontinence (with a major stress incontinence part) troubles * spontaneously asking for help * who can be followed for a long time

Exclusion criteria

* Urinary Incontinence (UI) found out during medical interviewing without spontaneous complaint * Urinary troubles due to neurological pathology (stroke, multiple sclerosis, ...) * UI due to congenital malformation * UI having led to surgery * UI treated in the last 6 months * UI within 24 weeks of Past Partum * Pelvic surgery within 12 months * On-going inflammatory or infectious neoplastic disease * Perineal hypoesthesia * Local conditions prohibiting the use of an intra-vaginal device (vaginal atrophia, continuous metrorrhagia, vaginal prolapse \> 2°, ...) * Pacemaker use * Women of child bearing potential without effective method of contraception or planning to get pregnant in the next 12 months * Intravaginal contraception * Mental impairment or inability to understand or follow study instructions * Patient who may not come back to the study visits * Patient already enrolled for another study or having been enrolled in another clinical study in the past 3 months

Design outcomes

Primary

MeasureTime frameDescription
Non-Worsening of ICIQ + Ditrovie Scales' Scores6 Months (or last measurement if premature ending)The primary outcome is defined as the non worsening of the ICIQ (International Consultation on Incontinence modular Questionnaire) scale's score AND the DITROVIE scale's score (a specific scale to evaluate the perturbation of the quality of life during urinary troubles). The scores will be considered as maintained if they didn't increase more than 10% with the following calculation: ICIQ variation (%) = 100 x (ICIQ\_M6 - ICIQ\_D0)/ICIQ\_D0 DITROVIE variation (%) = 100 x (DITROVIE\_M6 - DITROVIE\_D0)/(DITROVIE\_D0 -10)

Secondary

MeasureTime frameDescription
ICIQ Score6 Months (or last measurement if premature ending)Quantitative analyses: * difference = ICIQ\_M6 - ICIQ\_D0 * variation (%)= 100 x (ICIQ\_M6 - ICIQ\_D0)/ICIQ\_D0 Qualitative analysis \* % of patients with a variation % \<-10%, between -10% and +10%, \>10%
DITROVIE Score6 Months (or least measurement if premature ending)Quantitative analyses: * difference = DITROVIE\_M6 - DITROVIE\_D0 * variation (%)= 100 x (DITROVIE\_M6 - DITROVIE\_D0)/(DITROVIE\_D0 - 10) Qualitative analysis \* % of patients with a variation % \<-10%, between -10% and +10%, \>10%
ICG score6 Months (or last measurement if premature ending)The ICG (clinical global impression) score is the subjective impression of the patient regarding the evolution of her own clinical condition. It will be determined between inclusion and M6 (or the last visit).
HAD (Hospital Anxiety and Depression) scale6 months (or last measurement if premature ending)Qualitative analysis: * improvement from sub-score \> 10 to sub-score \< 10 * no change * worsening from sub-score \< 10 to sub-score \> 10
Bladder diary6 Months (or last visit if premature ending)A bladder diary will be filled by the patient for 3 days before the inclusion visit and then for 3 days before the final visit. The following items will be compared between D0 and M6: normal urinary episodes, incontinence episodes and drinks, in number and volume. Difference = M6 - D0 Variation % = 100 x (M6-D0)/D0
SF-12 Health Survey (Medical Outcomes Study Short-Form General Health Survey)6 Months (or last measurement if premature ending)Difference = M6 -D0 Variation % = 100 x (M6 - D0)/D0

Other

MeasureTime frameDescription
Adverse Events6 Months
Compliance6 MonthsThe lasts electro-stimulation sessions are recorded by the medical device.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026